Last reviewed · How we verify
IFX-1
At a glance
| Generic name | IFX-1 |
|---|---|
| Also known as | CaCP29, Vilobelimab |
| Sponsor | InflaRx GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. (PHASE2)
- Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum (PHASE2)
- Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia (PHASE2, PHASE3)
- Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. (PHASE2)
- Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA (PHASE2)
- Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (PHASE2)
- Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa (PHASE2)
- Studying Complement Inhibition in Complex Cardiac Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IFX-1 CI brief — competitive landscape report
- IFX-1 updates RSS · CI watch RSS
- InflaRx GmbH portfolio CI